News and Events
Epic Sciences Receives CE Mark for Liquid Biopsy Test Collection Kit. Enables Expanded Access to the Company’s Portfolio of Tests
San Diego – April 23, 2019 – Epic Sciences (“Epic”) announced today that it has received a CE mark for its Liquid Biopsy Test Collection Kit, allowing for sale and distribution of the company’s products within the European Economic Area (EEA). This kit is compatible with Epic’s rapidly expanding menu of diagnostic and clinical trial tests, including those for interventional use.
Epic Sciences Appoints Richard J. Wenstrup, M.D. as Chief Medical Officer
San Diego, CA, April 22, 2019. -- Epic Sciences, Inc. announced today the appointment of Richard J. Wenstrup, M.D. as chief medical officer. In this role, Dr. Wenstrup will lead clinical development, regulatory and medical affairs strategies for the company and be responsible for advancing the company’s clinical research and product development pipeline.
Epic Sciences Unveils New Liquid Biopsy Test to Predict Sensitivity to PARP Inhibitors in Prostate Cancer Trial
SAN DIEGO, April 3, 2019 – Epic Sciences, Inc. and its research partners today report the use of the company’s new circulating tumor cell (CTC) homologous recombination deficiency (HRD) liquid biopsy assay for the prediction of drug resistance in patients with metastatic castration-resistant prostate cancer (mCRPC). The assay is being utilized as a selection device in BeiGene, Ltd.’s ongoing Phase 2 clinical trial with its investigational PARP inhibitor (pamiparib) in this patient population (NCT03712930).
Epic Sciences Appoints Lloyd Sanders as Chief Executive Officer
SAN DIEGO, Calif., March 25, 2019 – Epic Sciences, Inc. (Epic) today announced that Lloyd Sanders has joined the company as president and chief executive officer. After serving nearly six years in the role, Murali Prahalad, Ph.D., has stepped down to pursue new opportunities and has been appointed to Epic’s board of directors.
Epic Sciences to Present New Data at AACR 2019 Demonstrating Expansion of Functional Cell Profiling Technology into New Indications including Breast, Lung and Prostate Cancer
SAN DIEGO – March 21, 2019 – Epic Sciences, Inc. announced today that new data will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2019, in Atlanta, Georgia, March 29 to April 4, 2019. The data from multiple studies and indications demonstrate the feasibility of Epic’s Functional Cell Profiling (FCP) technology to predict patients’ response to cancer immunotherapies and drugs that target DNA damage repair pathways.
Calendar of Events
American Association for Cancer Research Annual Meeting in Atlanta, GA from March 29 - April 3, 2019.
ASCO GU 2019
ASCO Genitourinary Cancer Symposiums Annual Meeting in San Francisco, CA from February 14 - 16, 2019.
In the News
Epic Sciences unveils new liquid biopsy test to predict sensitivity to PARP inhibitors in prostate cancer trial
Epic Sciences and its research partners report the use of the company's new circulating tumor cell (CTC) homologous recombination deficiency (HRD) liquid biopsy assay for the prediction of drug resistance in patients with metastatic castration-resistant prostate cancer (mCRPC). The assay is being utilized as a selection device in BeiGene, Ltd.’s ongoing Phase 2 clinical trial with its investigational PARP inhibitor (pamiparib) in this patient population (NCT03712930).
A Fluid Future - Why are there inconsistencies between different liquid biopsy tests – and how can the field evolve to maximize accuracy and impact?
Advances in disease profiling over recent years have opened new doors in the quest for early diagnosis and personalized treatment, with metastatic prostate cancer being a case in point. As the most widespread malignancy affecting men in the USA – 174,650 new cases and 31,620 deaths are predicted for 2019 – prostate cancer research is crucial. One such breakthrough is the use of liquid biopsy tests to detect circulating tumor DNA (ctDNA) in patients’ blood, offering a minimally invasive method of disease profiling.
Epic Sciences nets Myriad’s cancer president to serve as its CEO
Liquid biopsy developer Epic Sciences has brought on Myriad Genetics’ oncology chief, Lloyd Sanders, to be its new president and CEO. Sanders takes over for Murali Prahalad—who is stepping down after six years to pursue new opportunities, according to the company—though Prahalad will maintain a seat on Epic’s board of directors.
Epic Sciences Nabs NY State Approval for AR-V7 Prostate Cancer Test
NEW YORK (360Dx) – Epic Sciences said today that its lab is now licensed by the New York State Department of Health to provide its Oncotype DX AR-V7 Nucleus Detect test for residents with metastatic castration-resistant prostate cancer.
AR-V7 status predicts abiraterone, enzalutamide response in mCRPC
The PROPHECY study represents a multicenter effort that provides prospective, blinded clinical validation around such an approach and suggests that both the JHU CTC AR-V7 mRNA assay and the Epic CTC nuclear-specific AR-V7 protein assay provide clinical utility around the anticipated outcomes with therapy.
Every time Epic’s AR-V7 test is administered the healthcare system saves about $15,000 per year of life extended. In other words approximately $7,000 to $9,000 per patient tested.
Of the roughly 30 million cells in a typical blood sample, about 5 are cancer cells on their way to form tumors elsewhere in the body. Modern cancer diagnostics technology can't see them.
We spend about $100 billion a year on cancer drugs. But because we’re not matching the right drug to the right patient and their disease in a personalized way, about 3/4ths of that drug spend is wasted.
The Epic approach answers a critical question for a doctor: When is a patient resistant? By answering that question accurately and precisely we increase patient life and save the system money at the same time.
Today, Epic Sciences is embedded in clinical trials with 48 leading producers of oncology drugs and 35 of the top academic cancer hospitals.
It takes only 7 minutes to acquire an entire image of 6 million stained cells on a 1 x 3 slide. Then that image, which is about 20GB of data, gets sent up to the cloud where the algorithms run and find the rare events in about 2 more minutes.